With reference to the observation received from Bombay Stock Exchange dated November 28, 2018 for the in principal approval for Right Issue, Lasa Supergenerics has submitted the Signed Standalone Financial Results for the quarter and year ended March 31, 2018 along with auditors report.
The above information is a part of company’s filings submitted to BSE.